Serum Anti-Apo B Antibody Level as Residual CVD Marker in DM Patients under Statin Treatment

• Published in: Journal of Atherosclerosis and Thrombosis Vol. 26; no. 10; pp. 931 - 943
• Main Authors: Yamamoto, Hiroyasu, Kawamura, Mari, Kochi, Ikoi, Imai, Minami, Murata, Yukie, Suzuki, Toshinobu, Chen, Yingchao, Hashimoto, Kunihiko, Kihara, Shinji
• Format: Journal Article
• Language: English; Japanese
• Published: Japan Japan Atherosclerosis Society 01.10.2019
• Subjects: Adult; Aged; Aged, 80 and over; Apolipoprotein B-100; Apolipoprotein B-100 - immunology; Autoantibodies - blood; Autoantibodies - immunology; Autoantibody; Cardiovascular disease; Cardiovascular Diseases - blood; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - etiology; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Cardiomyopathies - blood; Diabetic Cardiomyopathies - diagnosis; Diabetic Cardiomyopathies - etiology; Disease Progression; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Male; Middle Aged; Original; Prognosis; Autoantibody; Apolipoprotein B-100; Cardiovascular disease; Diabetes
• ISSN: 1340-3478; 1880-3873
• DOI: 10.5551/jat.46797

Aim: In the pathogenesis of atherosclerosis, autoantibodies have two-facedness of progression and protection. Previous reports have indicated that low autoantibody levels against apolipoprotein B-100 (apo B-100) could increase the risk of atherosclerotic cardiovascular diseases (CVD) in healthy subjects. In this study, we investigated the relationship between circulating anti-apo B-100 autoantibodies and the clinical parameters in Japanese diabetic patients with or without CVD.Methods: We measured the serum levels of anti-apo B-100 autoantibodies against native and malondialdehyde (MDA)-modified p45 or p210 epitopes, as well as anti-apo E autoantibodies, using enzyme-linked immunosorbent assay.Results: In patients with CVD, the circulating levels of IgG against native p45, MDA-modified p45, and MDA-modified p210 (IgGN-45, IgGMDA-45, and IgGMDA-210) were significantly lower than those in patients without CVD, whereas no difference was observed in anti-apo E autoantibody levels. In addition, IgMN-45, IgMMDA-45, and IgGMDA-45 were negatively correlated with LDL-C levels, whereas IgGN-45 and IgGN-210 were positively correlated with HbA1c levels. No correlation was observed between autoantibody levels and diabetic microangiopathy. In the statin-treated subgroup, IgGMDA-45 and IgGMDA-210 were significantly lower in patients with CVD than in those without CVD.Conclusion: Measurement of serum anti-apo B-100 autoantibodies can be useful for the evaluation of CVD risk in patients with diabetes receiving statin treatment.